The Association Between Rad23b Ala249val Polymorphism and Cancer Susceptibility: Evidence from A Meta-Analysis

Zhenjun Li,Yan Zhang,Xiaojiang Ying,Junmin Song,Ruoxin Zhang,Zhen Li,Hongliang Chen,Pingjiang Ye,Yi Shen,Weihuo Pan,Zhiliang Chen
DOI: https://doi.org/10.1371/journal.pone.0091922
IF: 3.7
2014-01-01
PLoS ONE
Abstract:Background: A number of studies have investigated associations of genetic variation in RAD23B Ala249Val (rs1805329 C>T) with cancer susceptibility; however, the findings are inconsistent. We performed a meta-analysis to acquire a more precise estimation of the relationship.Method: We searched literatures from PubMed, Embase and Web of Science. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the association between Ala249Val polymorphism and cancer risk.Results: A total of 23 studies consisting of 10837 cases and 13971 controls were included in this meta-analysis. Overall, no significant associations were found between RAD23B Ala249Val polymorphism and cancer risk (Val/Val vs. Ala/Ala: OR = 0.97, 95% CI = 0.75-1.25; Ala/Val vs. Ala/Ala: OR = 1.08, 95% CI = 0.96-1.22; recessive model: OR = 0.93, 95% CI = 0.76-1.14 and dominant model: OR = 1.07, 95% CI = 0.94-1.20). We did not find any significant associations in the further stratification analyses by cancer type, ethnicity and source of control.Conclusions: Despite some limitations, this meta-analysis indicates that it is unlikely that the RAD23B 249Val/Val polymorphism may contribute to the individual susceptibility to cancer risk. However, further advanced designed studies with larger sample size and different ethnicities should be conducted to confirm our results.
What problem does this paper attempt to address?